Stanley-Laman Group
IONS icon

Stanley-Laman Group’s Ionis Pharmaceuticals IONS Stock Holding History

Stanley-Laman Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-60,842
Closed -$4.82M – 305
2026
Q2 		$4.82M Buy
60,842
+21,536
+55% +$1.62M 0.49% 55
2026
Q1 		$2.95M Buy
39,306
+2,794
+8% +$221K 0.36% 107
2025
Q4 		$2.89M Buy
36,512
+738
+2% +$55.6K 0.37% 104
2025
Q3 		$2.34M Buy
+35,774
New +$1.75M 0.33% 113

Other funds holding IONS

Pinnacle Associates
Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Nicollet Investment Management
Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Stanley-Laman Group's IONS Position: Q3 2026 in Review

Stanley-Laman Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2026, closing a stake of 60,842 shares — an estimated $4.82M sold.

Stanley-Laman Group first reported a position in IONS in Q3 2025 and held it in 4 quarters. The position peaked at $4.82M in Q2 2026. 60 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Stanley-Laman Group reported no remaining Ionis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Stanley-Laman Group sold 60,842 Ionis Pharmaceuticals shares in Q3 2026, an estimated $4.82M.
  • Stanley-Laman Group first reported a position in Ionis Pharmaceuticals in Q3 2025 and held it in 4 quarters.
  • Stanley-Laman Group's Ionis Pharmaceuticals position peaked at $4.82M in Q2 2026.
  • 60 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.